Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act
Latest action (28 Jun 2013): Introduced
What this bill does
H.R. 2607, the Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act, would reauthorize and modify federal programs addressing childhood, adolescent, and young adult cancer. It amends the Public Health Service Act to allow the Secretary of Health and Human Services, through the National Institutes of Health, to fund "Comprehensive Children's Cancer Biorepositories" that collect biospecimens and clinical/demographic data from at least 90 percent of young cancer patients, subject to privacy protections and parental or patient consent. It also revises grants to state cancer registries, administered through the CDC, to improve tracking of childhood cancer cases and their long-term effects, and requires coordination between the biorepository and registry programs. Funding authorization for the biorepository program is set at $10,000,000 through 2018. Separately, the bill requires a report from the Comptroller General on barriers to studying cancer drugs in children.
The bill primarily affects federal health agencies (NIH, CDC, FDA), state cancer registries, researchers, and children, adolescents, and young adults with cancer and their families, by shaping how their treatment data and biospecimens may be collected, stored, and shared for research purposes.
The bill was introduced in the House on June 28, 2013, by Representative Van Hollen and referred to the Committee on Energy and Commerce. It did not receive a vote and did not become law during the 113th Congress.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - Amends the Public Health Service Act to reauthorize through FY2018 cancer research programs under the Caroline Pryce Walker Conquer Childhood Cancer Act of 2008.
Replaces the current pediatric cancer research and awareness grant program carried out by the Secretary of Health and Human Services (HHS) with a comprehensive children's cancer biorepositories program.
Authorizes the Director of the National Institutes of Health (NIH) to make awards to eligible applicants to build upon existing initiatives to collect biospecimens and clinical and demographic information (including date of diagnosis, age at diagnosis, and patient's gender, race, and ethnicity) for at least 90% of all children, adolescents, and young adults with cancer in Comprehensive Children's Cancer Biorepositories for the purpose of achieving a better understanding of the cause of such cancers and the effects of treatments.
Permits award amounts to be used to: (1) acquire, preserve, and store high quality, donated biospecimens and associated clinical and demographic information on children, adolescents, and young adults diagnosed with cancer in the United States; (2) maintain a secure searchable database for scientists and qualified health care professionals to research such biospecimens and data; and (3) make available and distribute such biospecimens and data to researchers and professionals for peer-reviewed research.
Revises the national childhood cancer registry grant program to require the Director of the Centers for Disease Control and Prevention (CDC) to award grants to state cancer registries to enhance and expand infrastructure to track the epidemiology of cancer in children, adolescents, and young adults.
Requires a Comptroller General (GAO) report regarding the barriers to conducting pediatric studies of oncologic therapies in applications for new drugs or biological products under the Federal Food, Drug, and Cosmetic Act, including recommendations to improve development and access to new therapies as well as assessments of: (1) the feasibility of requiring studies for a pediatric oncologic indication if the therapeutic target of a drug or biologic product for an adult oncologic indication is highly relevant to any pediatric cancer to which it could apply, and (2) the impact of altering the current exemption for orphan drug designations relating to rare diseases or conditions.
Common questions
- What does H.R. 2607 do?
- H.R. 2607, the Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act, would reauthorize and modify federal programs addressing childhood, adolescent, and young adult cancer. It amends the Public Health Service Act to allow the Secretary of Health and Human Services, through the National Institutes of Health, to fund "Comprehensive Children's Cancer Biorepositories" that collect biospecimens and clinical/demographic data from at least 90 percent of young cancer patients, subject to privacy protections and parental or patient consent. It also revises grants to state cancer registries, administered through the CDC, to improve tracking of childhood cancer cases and their long-term effects, and requires coordination between the biorepository and registry programs. Funding authorization for the biorepository program is set at $10,000,000 through 2018. Separately, the bill requires a report from the Comptroller General on barriers to studying cancer drugs in children. The bill primarily affects federal health agencies (NIH, CDC, FDA), state cancer registries, researchers, and children, adolescents, and young adults with cancer and their families, by shaping how their treatment data and biospecimens may be collected, stored, and shared for research purposes. The bill was introduced in the House on June 28, 2013, by Representative Van Hollen and referred to the Committee on Energy and Commerce. It did not receive a vote and did not become law during the 113th Congress.
- Has H.R. 2607 become law?
- Not yet. As of 28 Jun 2013, H.R. 2607 is introduced.
- Who sponsored H.R. 2607?
- H.R. 2607 was sponsored by Sen. Chris Van Hollen [D-MD] (Democrat-MD), with 73 cosponsors.
- What's the latest action on H.R. 2607?
- Introduced (28 Jun 2013).
Related bills in Health
Expressing support for the designation of September 22, 2026, as “National Hispanic Nurses Day” and recognizing the National Association of Hispanic Nurses as the leading organization representing and advocating for Hispanic nurses.
Recognizing the importance of protecting continuous Medicaid coverage for individuals undergoing active cancer treatment.
Expressing support for the designation of the third week of September as “Fungal Disease Awareness Week” and encouraging efforts to improve awareness, diagnosis, treatment, surveillance, and prevention of fungal diseases in the United States.
A resolution supporting the designation of October 2026 as “Substance Use & Misuse Prevention Month” to raise awareness of substance use and misuse in the United States.
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.